

George Bertσίας

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/143016/publications.pdf>

Version: 2024-02-01

221
papers

13,241
citations

47006

47
h-index

24258

110
g-index

228
all docs

228
docs citations

228
times ranked

11566
citing authors

#	ARTICLE	IF	CITATIONS
1	2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 736-745.	0.9	1,265
2	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. <i>Arthritis and Rheumatology</i> , 2019, 71, 1400-1412.	5.6	1,098
3	Joint European League Against Rheumatism and European Renal Association "European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of adult and paediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, 1771-1782.	0.9	868
4	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1151-1159.	0.9	759
5	EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. <i>Annals of the Rheumatic Diseases</i> , 2008, 67, 195-205.	0.9	645
6	EULAR recommendations for women's health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 476-485.	0.9	590
7	EULAR recommendations for the management of systemic lupus erythematosus with neuropsychiatric manifestations: report of a task force of the EULAR standing committee for clinical affairs. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2074-2082.	0.9	578
8	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 958-967.	0.9	558
9	Genome-wide association analysis identifies new susceptibility loci for Behçet's disease and epistasis between HLA-B*51 and ERAP1. <i>Nature Genetics</i> , 2013, 45, 202-207.	21.4	483
10	2019 Update of the Joint European League Against Rheumatism and European Renal Association "European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations for the management of lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 713-723.	0.9	463
11	Update in the diagnosis and management of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 14-25.	0.9	312
12	Identification of novel microRNA signatures linked to human lupus disease activity and pathogenesis: miR-21 regulates aberrant T cell responses through regulation of PDCD4 expression. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 1496-1506.	0.9	276
13	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 554-561.	0.9	268
14	Pathogenesis, diagnosis and management of neuropsychiatric SLE manifestations. <i>Nature Reviews Rheumatology</i> , 2010, 6, 358-367.	8.0	218
15	Expansion of toll-like receptor 9-expressing B cells in active systemic lupus erythematosus: Implications for the induction and maintenance of the autoimmune process. <i>Arthritis and Rheumatism</i> , 2006, 54, 3601-3611.	6.7	170
16	REDD1/autophagy pathway promotes thromboinflammation and fibrosis in human systemic lupus erythematosus (SLE) through NETs decorated with tissue factor (TF) and interleukin-17A (IL-17A). <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 238-248.	0.9	153
17	Anti-tumor necrosis factor therapy improves insulin resistance, beta cell function and insulin signaling in active rheumatoid arthritis patients with high insulin resistance. <i>Arthritis Research and Therapy</i> , 2012, 14, R141.	3.5	145
18	Metabolic syndrome is common among middle-to-older aged Mediterranean patients with rheumatoid arthritis and correlates with disease activity: a retrospective, cross-sectional, controlled, study. <i>Annals of the Rheumatic Diseases</i> , 2006, 66, 28-33.	0.9	129

#	ARTICLE	IF	CITATIONS
19	Performance of Antinuclear Antibodies for Classifying Systemic Lupus Erythematosus: A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Arthritis Care and Research</i> , 2018, 70, 428-438.	3.4	129
20	The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. <i>Arthritis and Rheumatism</i> , 2010, 62, 1870-1880.	6.7	126
21	Enhanced activity of NLRP3 inflammasome in peripheral blood cells of patients with active rheumatoid arthritis. <i>Arthritis Research and Therapy</i> , 2015, 17, 257.	3.5	125
22	Overweight and obesity in relation to cardiovascular disease risk factors among medical students in Crete, Greece. <i>BMC Public Health</i> , 2003, 3, 3.	2.9	121
23	Therapeutic opportunities in systemic lupus erythematosus: state of the art and prospects for the new decade. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 1603-1611.	0.9	121
24	Combined genetic and transcriptome analysis of patients with SLE: distinct, targetable signatures for susceptibility and severity. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1079-1089.	0.9	109
25	Rituximab therapy reduces activated B cells in both the peripheral blood and bone marrow of patients with rheumatoid arthritis: depletion of memory B cells correlates with clinical response. <i>Arthritis Research and Therapy</i> , 2009, 11, R131.	3.5	103
26	Diagnostic criteria for systemic lupus erythematosus: has the time come?. <i>Nature Reviews Rheumatology</i> , 2013, 9, 687-694.	8.0	103
27	Toll like receptors and autoimmunity: A critical appraisal. <i>Journal of Autoimmunity</i> , 2007, 29, 310-318.	6.5	101
28	Genetic, immunologic, and immunohistochemical analysis of the programmed death 1/programmed death ligand 1 pathway in human systemic lupus erythematosus. <i>Arthritis and Rheumatism</i> , 2009, 60, 207-218.	6.7	99
29	Lupus nephritis management guidelines compared. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 904-913.	0.7	97
30	IFN γ Impairs Autophagic Degradation of mtDNA Promoting Autoreactivity of SLE Monocytes in a STING-Dependent Fashion. <i>Cell Reports</i> , 2018, 25, 921-933.e5.	6.4	97
31	2021 DORIS definition of remission in SLE: final recommendations from an international task force. <i>Lupus Science and Medicine</i> , 2021, 8, e000538.	2.7	97
32	Update on the epidemiology, risk factors, and disease outcomes of systemic lupus erythematosus. <i>Best Practice and Research in Clinical Rheumatology</i> , 2018, 32, 188-205.	3.3	85
33	Comparative effectiveness and survival of infliximab, adalimumab, and etanercept for rheumatoid arthritis patients in the Hellenic Registry of Biologics: Low rates of remission and 5-year drug survival. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 447-457.	3.4	80
34	Neutrophil extracellular traps exacerbate Th1-mediated autoimmune responses in rheumatoid arthritis by promoting DC maturation. <i>European Journal of Immunology</i> , 2016, 46, 2542-2554.	2.9	75
35	In an early SLE cohort the ACR-1997, SLICC-2012 and EULAR/ACR-2019 criteria classify non-overlapping groups of patients: use of all three criteria ensures optimal capture for clinical studies while their modification earlier classification and treatment. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 232-241.	0.9	71
36	Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. <i>Rheumatology</i> , 2020, 59, v69-v81.	1.9	69

#	ARTICLE	IF	CITATIONS
37	Epidemiology and burden of systemic lupus erythematosus in a Southern European population: data from the community-based lupus registry of Crete, Greece. <i>Annals of the Rheumatic Diseases</i> , 2017, 76, 1992-2000.	0.9	68
38	Glomerular expression of toll-like receptor-9 in lupus nephritis but not in normal kidneys: implications for the amplification of the inflammatory response. <i>Lupus</i> , 2009, 18, 831-835.	1.6	62
39	Gene expression in systemic lupus erythematosus: Bone marrow analysis differentiates active from inactive disease and reveals apoptosis and granulopoiesis signatures. <i>Arthritis and Rheumatism</i> , 2008, 58, 3541-3549.	6.7	61
40	Cardiovascular Disease in Systemic Lupus Erythematosus: Recent Data on Epidemiology, Risk Factors and Prevention. <i>Current Vascular Pharmacology</i> , 2020, 18, 549-565.	1.7	61
41	Low disease activity“irrespective of serologic status at baseline“associated with reduction of corticosteroid dose and number of flares in patients with systemic lupus erythematosus treated with belimumab: A real-life observational study. <i>Seminars in Arthritis and Rheumatism</i> , 2018, 48, 467-474.	3.4	59
42	Cigarette smoking, alcohol consumption, and serum lipid profile among medical students in Greece. <i>European Journal of Public Health</i> , 2003, 13, 278-282.	0.3	57
43	Clinical trials in systemic lupus erythematosus (SLE): lessons from the past as we proceed to the future “ the EULAR recommendations for the management of SLE and the use of end-points in clinical trials. <i>Lupus</i> , 2008, 17, 437-442.	1.6	56
44	Flares in systemic lupus erythematosus: diagnosis, risk factors and preventive strategies. <i>Mediterranean Journal of Rheumatology</i> , 2017, 28, 4-12.	0.8	54
45	A common SNP in the CD40 region is associated with systemic lupus erythematosus and correlates with altered CD40 expression: implications for the pathogenesis. <i>Annals of the Rheumatic Diseases</i> , 2011, 70, 2184-2190.	0.9	53
46	Immunometabolism: an overview and therapeutic prospects in autoimmune diseases. <i>Immunotherapy</i> , 2019, 11, 813-829.	2.0	53
47	Gene expression and regulation in systemic lupus erythematosus. <i>European Journal of Clinical Investigation</i> , 2013, 43, 1084-1096.	3.4	52
48	Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 758-766.	0.9	50
49	Pathogenesis and treatment of CNS lupus. <i>Current Opinion in Rheumatology</i> , 2013, 25, 577-583.	4.3	49
50	Infliximab treatment for rheumatoid arthritis, with dose titration based on the Disease Activity Score: dose adjustments are common but not always sufficient to assure sustained benefit. <i>Annals of the Rheumatic Diseases</i> , 2004, 63, 144-148.	0.9	48
51	EULAR recommendations for neuropsychiatric systemic lupus erythematosus vs usual care: results from two European centres. <i>Rheumatology</i> , 2015, 54, 1270-1278.	1.9	48
52	Sexual dimorphism in SLE: above and beyond sex hormones. <i>Lupus</i> , 2019, 28, 3-10.	1.6	48
53	Dietary and other lifestyle correlates of serum folate concentrations in a healthy adult population in Crete, Greece: a cross-sectional study. <i>Nutrition Journal</i> , 2006, 5, 5.	3.4	47
54	Cyclophosphamide in combination with glucocorticoids for severe neuropsychiatric systemic lupus erythematosus: a retrospective, observational two-centre study. <i>Lupus</i> , 2016, 25, 627-636.	1.6	45

#	ARTICLE	IF	CITATIONS
55	Elimination of Granulocytic Myeloid-Derived Suppressor Cells in Lupus-Prone Mice Linked to Reactive Oxygen Species-Dependent Extracellular Trap Formation. <i>Arthritis and Rheumatology</i> , 2016, 68, 449-461.	5.6	44
56	Transcriptome reprogramming and myeloid skewing in haematopoietic stem and progenitor cells in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 242-253.	0.9	44
57	Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 441-448.	0.9	43
58	Systemic Lupus Erythematosus in Primary Care: An Update and Practical Messages for the General Practitioner. <i>Frontiers in Medicine</i> , 2018, 5, 161.	2.6	42
59	Changing paradigms in the treatment of systemic lupus erythematosus. <i>Lupus Science and Medicine</i> , 2019, 6, e000310.	2.7	40
60	Management of lupus nephritis: a systematic literature review informing the 2019 update of the joint EULAR and European Renal Association-European Dialysis and Transplant Association (EULAR/ERA-EDTA) recommendations. <i>RMD Open</i> , 2020, 6, e001263.	3.8	39
61	Update on the management of lupus nephritis: let the treatment fit the patient. <i>Nature Clinical Practice Rheumatology</i> , 2008, 4, 464-472.	3.2	38
62	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 775-781.	0.9	37
63	EULAR points to consider for conducting clinical trials in systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 470-476.	0.9	36
64	Consumption of Ready-to-Eat Cereals in Relation to Health and Diet Indicators among School Adolescents in Crete, Greece. <i>Annals of Nutrition and Metabolism</i> , 2005, 49, 165-172.	1.9	35
65	Validity of the Italian algorithm for the attribution of neuropsychiatric events in systemic lupus erythematosus: a retrospective multicentre international diagnostic cohort study. <i>BMJ Open</i> , 2017, 7, e015546.	1.9	35
66	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 1333-1339.	0.9	35
67	Gene Network Analysis of Bone Marrow Mononuclear Cells Reveals Activation of Multiple Kinase Pathways in Human Systemic Lupus Erythematosus. <i>PLoS ONE</i> , 2010, 5, e13351.	2.5	33
68	EULAR points to consider for conducting clinical trials in systemic lupus erythematosus: literature based evidence for the selection of endpoints: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2009, 68, 477-483.	0.9	30
69	Fruit and Vegetables Consumption in Relation to Health and Diet of Medical Students in Crete, Greece. <i>International Journal for Vitamin and Nutrition Research</i> , 2005, 75, 107-117.	1.5	28
70	Update on the cellular and molecular aspects of lupus nephritis. <i>Clinical Immunology</i> , 2020, 216, 108445.	3.2	28
71	NETs decorated with bioactive IL-33 infiltrate inflamed tissues and induce IFN- γ production in patients with SLE. <i>JCI Insight</i> , 2021, 6, .	5.0	28
72	Nutrient intake and food consumption among medical students in Greece assessed during a Clinical Nutrition course. <i>International Journal of Food Sciences and Nutrition</i> , 2004, 55, 17-26.	2.8	27

#	ARTICLE	IF	CITATIONS
73	Infections in patients with traumatic brain injury who undergo neurosurgery. <i>British Journal of Neurosurgery</i> , 2011, 25, 9-15.	0.8	27
74	The Effect of Periodic Vegetarianism on Serum Retinol and Î±-tocopherol Levels. <i>International Journal for Vitamin and Nutrition Research</i> , 2009, 79, 271-280.	1.5	26
75	Coexistence of systemic lupus erythematosus and multiple sclerosis: Prevalence, clinical characteristics, and natural history. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 43, 751-758.	3.4	26
76	Canakinumab for recurrent rheumatic disease associated-pericarditis: a case series with long-term follow-up. <i>Rheumatology</i> , 2018, 57, 1494-1495.	1.9	26
77	High Comorbidity Burden in Patients with SLE: Data from the Community-Based Lupus Registry of Crete. <i>Journal of Clinical Medicine</i> , 2021, 10, 998.	2.4	26
78	Optimum therapeutic approaches for lupus nephritis: what therapy and for whom?. <i>Nature Clinical Practice Rheumatology</i> , 2005, 1, 22-30.	3.2	25
79	Comparable or higher prevalence of comorbidities in antiphospholipid syndrome <i>vs</i> rheumatoid arthritis: a multicenter, case-control study. <i>Rheumatology</i> , 2021, 60, 170-178.	1.9	24
80	Achieving remission or low disease activity is associated with better outcomes in patients with systemic lupus erythematosus: a systematic literature review. <i>Lupus Science and Medicine</i> , 2021, 8, e000542.	2.7	24
81	Is it primary neuropsychiatric systemic lupus erythematosus? Performance of existing attribution models using physician judgment as the gold standard. <i>Clinical and Experimental Rheumatology</i> , 2016, 34, 910-917.	0.8	24
82	Cognitive deficits early in the course of rheumatoid arthritis. <i>Journal of Clinical and Experimental Neuropsychology</i> , 2016, 38, 820-829.	1.3	23
83	Metabolic syndrome in children and adolescents in Crete, Greece, and association with diet quality and physical fitness. <i>Zeitschrift Fur Gesundheitswissenschaften</i> , 2008, 16, 421-428.	1.6	22
84	Clinical and financial burden of active lupus in Greece: a nationwide study. <i>Lupus</i> , 2016, 25, 1385-1394.	1.6	22
85	Micro-RNA analysis of renal biopsies in human lupus nephritis demonstrates up-regulated miR-422a driving reduction of kallikrein-related peptidase 4. <i>Nephrology Dialysis Transplantation</i> , 2016, 31, 1676-1686.	0.7	22
86	Programmed death 1 and B and T lymphocyte attenuator immunoreceptors and their association with malignant Tâ€lymphoproliferative disorders: brief review. <i>Hematological Oncology</i> , 2014, 32, 113-119.	1.7	21
87	An Update on the Diagnosis and Management of Lupus Nephritis. <i>Current Rheumatology Reports</i> , 2020, 22, 30.	4.7	21
88	Development and preliminary validation of the BehÃsetâ€™s syndrome Overall Damage Index (BODI). <i>RMD Open</i> , 2020, 6, e001192.	3.8	20
89	Cytokine targets in lupus nephritis: Current and future prospects. <i>Clinical Immunology</i> , 2019, 206, 42-52.	3.2	18
90	Quantitative Identification of Functional Connectivity Disturbances in Neuropsychiatric Lupus Based on Resting-State fMRI: A Robust Machine Learning Approach. <i>Brain Sciences</i> , 2020, 10, 777.	2.3	18

#	ARTICLE	IF	CITATIONS
91	Regional cerebral perfusion correlates with anxiety in neuropsychiatric SLE: evidence for a mechanism distinct from depression. <i>Lupus</i> , 2019, 28, 1678-1689.	1.6	17
92	Physician Global Assessment International Standardisation COnsensus in Systemic Lupus Erythematosus: the PISCOS study. <i>Lancet Rheumatology</i> , The, 2022, 4, e441-e449.	3.9	17
93	Inhibition of tumour necrosis factor alpha in idiopathic membranous nephropathy: a pilot study. <i>Nephrology Dialysis Transplantation</i> , 2009, 24, 2144-2150.	0.7	16
94	Lupus nephritis“winning a few battles but not the war. <i>Nature Reviews Rheumatology</i> , 2011, 7, 441-442.	8.0	15
95	Vaccination against Human Papillomavirus in relation to Financial Crisis: The “Evaluation and Education of Greek Female Adolescents on Human Papillomaviruses” Prevention Strategies“ELEFThERIA Study. <i>Journal of Pediatric and Adolescent Gynecology</i> , 2016, 29, 362-366.	0.7	15
96	A decade of mycophenolate mofetil for lupus nephritis: is the glass half-empty or half-full?. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, 2059-2061.	0.9	14
97	Cyclophosphamide and Lupus Nephritis: When, How, For How Long?. <i>Clinical Reviews in Allergy and Immunology</i> , 2011, 40, 181-191.	6.5	14
98	Population-based studies in systemic lupus erythematosus: immune thrombocytopenic purpura or “blood-dominant” lupus?. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 683-684.	0.9	14
99	Therapeutic targeting of JAKs: from hematology to rheumatology and from the first to the second generation of JAK inhibitors. <i>Mediterranean Journal of Rheumatology</i> , 2020, 31, 105.	0.8	13
100	Review of clinical and toxicological features of acute pesticide poisonings in Crete (Greece) during the period 1991-2001. <i>Medical Science Monitor</i> , 2004, 10, CR622-7.	1.1	12
101	Hair analysis differentiates chronic from acute carbamazepine intoxication. <i>Pediatric Neurology</i> , 2004, 31, 73-75.	2.1	11
102	Dysregulated production of interleukin-1 ^β upon activation of the NLRP3 inflammasome in patients with familial Mediterranean fever. <i>Human Immunology</i> , 2015, 76, 488-495.	2.4	11
103	Hydroxychloroquine dosing in systemic lupus erythematosus: response to “Comment on the 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus by Fanouriakis et al” by Costedoat-Chalumeau et al. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, e91-e91.	0.9	11
104	Is systemic lupus erythematosus different in urban versus rural living environment? Data from the Cretan Lupus Epidemiology and Surveillance Registry. <i>Lupus</i> , 2019, 28, 104-113.	1.6	10
105	Treatment of neuropsychiatric systemic lupus erythematosus: clinical challenges and future perspectives. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 317-329.	3.0	10
106	Lupus Nephritis: Improving Treatment Options. <i>Drugs</i> , 2022, 82, 735-748.	10.9	10
107	Molecular Taxonomy of Systemic Lupus Erythematosus Through Data-Driven Patient Stratification: Molecular Endotypes and Cluster-Tailored Drugs. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	10
108	2008“2018: a decade of recommendations for systemic lupus erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2018, 77, 1547-1548.	0.9	9

#	ARTICLE	IF	CITATIONS
109	Rheumatoid arthritis patients on persistent moderate disease activity on biologics have adverse 5-year outcome compared to persistent low-remission status and represent a heterogeneous group. <i>Arthritis Research and Therapy</i> , 2020, 22, 226.	3.5	9
110	Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state functional MRI study. <i>Lupus Science and Medicine</i> , 2021, 8, e000473.	2.7	9
111	Relevant domains and outcome measurement instruments in neuropsychiatric systemic lupus erythematosus: a systematic literature review. <i>Rheumatology</i> , 2021, 61, 8-23.	1.9	9
112	Quality indicators for systemic lupus erythematosus based on the 2019 EULAR recommendations: development and initial validation in a cohort of 220 patients. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 1175-1182.	0.9	9
113	Machine Learning Classification of Neuropsychiatric Systemic Lupus Erythematosus patients using resting-state fMRI functional connectivity. , 2019, , .		8
114	Extensive fragmentation and re-organization of transcription in Systemic Lupus Erythematosus. <i>Scientific Reports</i> , 2020, 10, 16648.	3.3	8
115	The association between lupus serology and disease outcomes: A systematic literature review to inform the treat-to-target approach in systemic lupus erythematosus. <i>Lupus</i> , 2022, , 096120332210745.	1.6	8
116	Recommendations for Systemic Lupus Erythematosus. <i>Rheumatic Disease Clinics of North America</i> , 2022, 48, 617-636.	1.9	8
117	Discordance between patient and physician global assessment of disease activity in Behçet's syndrome: a multicenter study cohort. <i>Arthritis Research and Therapy</i> , 2020, 22, 278.	3.5	7
118	Adaptation to an autoimmune disorder: Does mental flexibility impact illness-related self-regulation?. <i>Psychology and Health</i> , 2016, 31, 276-291.	2.2	6
119	FRIO193...2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE MANAGEMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		6
120	Demyelination with autoimmune features: a distinct clinical entity? Results from a longitudinal cohort. <i>Rheumatology</i> , 2021, 60, 4166-4174.	1.9	6
121	First Diagnosis of Systemic Lupus Erythematosus in Hospitalized Patients: Clinical Phenotypes and Pitfalls for the Non-Specialist. <i>American Journal of Medicine</i> , 2022, 135, 244-253.e3.	1.5	6
122	Changes in resting-state functional connectivity in neuropsychiatric lupus: A dynamic approach based on recurrence quantification analysis. <i>Biomedical Signal Processing and Control</i> , 2022, 72, 103285.	5.7	6
123	Suspected systemic rheumatic diseases in patients presenting with cytopenias. <i>Best Practice and Research in Clinical Rheumatology</i> , 2019, 33, 101425.	3.3	5
124	Editorial: Lupus and the Brain: Advances in Neuropsychiatric Systemic Lupus Erythematosus. <i>Frontiers in Medicine</i> , 2019, 6, 52.	2.6	5
125	Extensive Changes in Transcription Dynamics Reflected on Alternative Splicing Events in Systemic Lupus Erythematosus Patients. <i>Genes</i> , 2021, 12, 1260.	2.4	5
126	Screening for cognitive impairment in systemic lupus erythematosus: Application of the Montreal Cognitive Assessment (MoCA) in a Greek patient sample. <i>Lupus</i> , 2021, 30, 2237-2247.	1.6	5

#	ARTICLE	IF	CITATIONS
127	Treatment of lupus: more options after a long wait. <i>Annals of the Rheumatic Diseases</i> , 2022, 81, 753-756.	0.9	5
128	SAT0415â€¦Performance of Anti-Nuclear Antibodies (ANA) for Classifying Systemic Lupus Erythematosus (SLE): A Systematic Literature Review and Meta-Regression of Diagnostic Data. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 809.2-810.	0.9	4
129	Treat-to-target in lupus: what does the future hold?. <i>International Journal of Clinical Rheumatology</i> , 2015, 10, 461-477.	0.3	4
130	Adaptation to inflammatory rheumatic disease: Do illness representations predict patientsâ€™ physical functioning over time? A complex relationship. <i>Journal of Behavioral Medicine</i> , 2018, 41, 232-242.	2.1	4
131	Converging evidence of impaired brain function in systemic lupus erythematosus: changes in perfusion dynamics and intrinsic functional connectivity. <i>Neuroradiology</i> , 2022, 64, 1593-1604.	2.2	4
132	Pharmacotherapy of lupus nephritis: time for a consensus?. <i>Expert Opinion on Pharmacotherapy</i> , 2008, 9, 2099-2115.	1.8	3
133	Balancing efficacy and toxicity of novel therapies in systemic lupus erythematosus. <i>Expert Review of Clinical Pharmacology</i> , 2011, 4, 437-451.	3.1	3
134	AB0380â€¦Treat-to-target in systemic lupus erythematosus: report from the t2t/sle working party. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A903.2-A903.	0.9	3
135	Treatment of Systemic Lupus Erythematosus. , 2017, , 1368-1388.e5.		3
136	Response to: â€˜Correspondence on â€˜Lupus or not? SLE Risk Probability Index (SLERPI): a simple, clinician-friendly machine learning-based model to assist the diagnosis of systemic lupus erythematosusâ€™ by Batu<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e145-e145.	0.9	3
137	Epione application: An integrated webâ€™toolkit of clinical genomics and personalized medicine in systemic lupus erythematosus. <i>International Journal of Molecular Medicine</i> , 2021, 49, .	4.0	3
138	Whatâ€™s new in clinical trials in lupus?. <i>International Journal of Clinical Rheumatology</i> , 2009, 4, 473-485.	0.3	2
139	OP0064â€¦Joint EULAR/ERA-EDTA recommendations for the management of adult and pediatric lupus nephritis. <i>Annals of the Rheumatic Diseases</i> , 2013, 71, 74.3-75.	0.9	2
140	THU0367â€¦Familial Mediterranean Fever (FMF): A Single Center Clinical-Genetic Study: Table 1. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 309.2-309.	0.9	2
141	OP0086â€¦Eular Recommendations for Women's Health and the Management of Family Planning, Assisted Reproduction, Pregnancy, and Menopause in Patients With Systemic Lupus Erythematosus and/or the Antiphospholipid Syndrome. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 101.1-101.	0.9	2
142	Almost Half of Octogenarians and Nonagenarians Admitted Acutely to Internal Medicine Ward Die During Admission or Within 6 Months After Discharge: Time to Redefine Treatment Goals?. <i>Journal of the American Geriatrics Society</i> , 2015, 63, 380-383.	2.6	2
143	Cytotoxic-Immunosuppressive Drug Treatment. , 2016, , 533-541.		2
144	PS2:38â€¦Comparative tissue transcriptome analysis by next-generation sequencing reveals novel pathways that characterise genetic susceptibility and developmental biology in systemic lupus erythematosus (sle). , 2018, , .		2

#	ARTICLE	IF	CITATIONS
145	Reply. Arthritis Care and Research, 2019, 71, 696-697.	3.4	2
146	Development and Implementation of a Pilot Registry for Monitoring the Efficacy and Safety of Novel Therapies in Patients with Systemic Lupus Erythematosus. Mediterranean Journal of Rheumatology, 2019, 31, 87.	0.8	2
147	Genetic association and functional consequences of a common SNP in the CD40 region with systemic lupus erythematosus and rheumatoid arthritis in a homogeneous Greek population. Annals of the Rheumatic Diseases, 2011, 70, A14-A14.	0.9	1
148	Identification of a novel microRNA-gene circuit in human lupus nephritis: evidence for modulation of kallikrein genes by MIR-422A. Annals of the Rheumatic Diseases, 2012, 71, A51.1-A51.	0.9	1
149	SAT0006â€¦MicroRNA analysis of human lupus nephritis: Evidence for modulation of kallikrein 4 by MIR-422A. Annals of the Rheumatic Diseases, 2013, 71, 472.3-473.	0.9	1
150	OPO092â€¦Remission in Sle: Consensus Findings from a Large International Panel on Definitions of Remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2015, 74, 103.2-103.	0.9	1
151	A6.34â€¦The role of the costimulatory receptor herpes virus entry mediator (HVEM) in B-cell activation and differentiation. implications for SLE pathogenesis. Annals of the Rheumatic Diseases, 2015, 74, A69.3-A70.	0.9	1
152	Patient and partner dispositional optimism as a long-term predictor of illness representations in autoimmune diseases. Journal of Health Psychology, 2017, 22, 1691-1700.	2.3	1
153	Response to: 'Neuropsychiatric lupus or not? Cerebral hypoperfusion by perfusion-weighted MRI in normal-appearing white matter in primary neuropsychiatric lupus erythematosus' by Papadaki et al' by Wallace. Annals of the Rheumatic Diseases, 2019, 78, e6-e6.	0.9	1
154	Chloroquine as alternative antimalarial in systemic lupus erythematosus. Response to '2019 update of the EULAR recommendations for the management of SLE: don't forget chloroquine' by Figueroa-Parra et al. Annals of the Rheumatic Diseases, 2020, 79, e115-e115.	0.9	1
155	Response to: 'Treatment of systemic lupus erythematosus: don't forget hydroxychloroquine' by Michaud et al. Annals of the Rheumatic Diseases, 2020, 79, e134-e134.	0.9	1
156	Response to: 'Concerns about the operational definition of remission in 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus' by Rua-Figueroa and Erasquin. Annals of the Rheumatic Diseases, 2020, 79, e132-e132.	0.9	1
157	Response to: 'Bone health, an often forgotten comorbidity in systemic lupus erythematosus: a comment on the new recommendations' by Orsolini et al. Annals of the Rheumatic Diseases, 2020, 79, e151-e151.	0.9	1
158	POS0757â€¦SYSTEMIC LUPUS ERYTHEMATOSUS (SLE) DIAGNOSED DURING HOSPITALIZATION: CLINICAL PHENOTYPE AND PERFORMANCE OF THE SLE RISK PROBABILITY INDEX (SLERPI). Annals of the Rheumatic Diseases, 2021, 80, 631-631.	0.9	1
159	POS0759â€¦THE JOURNEY OF PATIENTS FROM FIRST SYMPTOMS TO DIAGNOSIS OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): AN OBSERVATIONAL STUDY. Annals of the Rheumatic Diseases, 2021, 80, 632.2-633.	0.9	1
160	Treatment of Systemic Lupus Erythematosus. , 2013, , 1304-1330.e6.		1
161	Title is missing!. Arthritis Research, 2005, 7, P144.	2.0	0
162	Title is missing!. Arthritis Research, 2005, 7, P153.	2.0	0

#	ARTICLE	IF	CITATIONS
163	Micro RNA analysis reveals novel genes in human systemic lupus erythematosus: miR-21 affects PDCD4 expression and regulates aberrant T cell responses. <i>Annals of the Rheumatic Diseases</i> , 2010, 69, A28-A28.	0.9	0
164	Regulation of T cell hyperactivity in SLE: the negative co-stimulatory molecule PD-1 regulates miR-21 expression in SLE T lymphocytes. <i>Annals of the Rheumatic Diseases</i> , 2012, 71, A58.1-A58.	0.9	0
165	An update on the management of comorbid conditions in lupus nephritis. <i>Clinical Investigation</i> , 2013, 3, 281-293.	0.0	0
166	A5.26â€¦Regulation of Expression and Function of Negative Immunomodulatory Receptors in B-Cells: Implications for the Pathogenesis of Systemic Lupus Erythematosus. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A40.1-A40.	0.9	0
167	AB0371â€¦State of the art for treating-to-target in sle: a systematic literature review. <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A900.4-A901.	0.9	0
168	A2.8â€¦Enhanced Neutrophil Extracellular Trap Formation in Rheumatoid Arthritis Patients is Correlated with High Levels of Rheumatoid Factor (RF). <i>Annals of the Rheumatic Diseases</i> , 2013, 72, A7.1-A7.	0.9	0
169	OP0283â€¦Increased Neutrophil Extracellular TRAP Formation in Rheumatoid Arthritis is Correlated with the Induction of Pathogenic Th1 And/Or TH17 Cell Responses. <i>Annals of the Rheumatic Diseases</i> , 2014, 73, 169.1-169.	0.9	0
170	AB1119â€¦The Cretan Lupus Registry â€œLetoâ€ Prevalence, Clinical Features and Environmental Factors in a Genetically Homogenous, Mixed Urban and Rural, South European Population. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 1275.1-1275.	0.9	0
171	AB0175â€¦Elimination of Granulocytic Myeloid-Derived Suppressor Cells in Lupus-Prone Mice Due to Ros-Dependent Extracellular Trap Formation. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 949.1-949.	0.9	0
172	A1.32â€¦The role of hematopoietic stem cells (HSC) in systemic autoimmunity. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A14.1-A14.	0.9	0
173	FRIO401â€¦Clinical and Financial Burden of SLE in Greece: A Nation-Wide, Multi-Centre Study. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, 571.3-572.	0.9	0
174	A2.23â€¦Deregulated, IFNA driven autophagy shapes the phenotype of autoreactive SLE monocytes. <i>Annals of the Rheumatic Diseases</i> , 2015, 74, A25.1-A25.	0.9	0
175	A6.08â€¦Transcriptome profiling by next generation sequencing of hematopoietic progenitors in murine systemic lupus erythematosus (SLE). <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A50.1-A50.	0.9	0
176	FRIO316â€¦Assessing Attribution of Neuropsychiatric Events in Systemic Lupus Erythematosus. Performance of A New Algorithm in An International Multicenter Cohort. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, 549.2-550.	0.9	0
177	O3.23â€¦Transcriptomic analysis of plasmacytoid dendritic cells from rheumatoid arthritis patients reveals novel targets for therapy. , 2017, , .		0
178	O8.31â€¦Unravelling the role of il33/st2l axis on sustained ifn-a production in systemic lupus erythematosus. , 2017, , .		0
179	OP0332â€¦The genomic architecture of systemic lupus erythematosus (SLE) by RNA-SEQ: distinct disease susceptibility, activity and severity signatures and extensive genetic effects on whole blood gene expression. , 2017, , .		0
180	THU0254â€¦Comparison of urban versus rural environment associated systemic lupus erythematosus (SLE): risk and clinical features. , 2017, , .		0

#	ARTICLE	IF	CITATIONS
181	SAT0204â€¦Abatacept survival in rheumatoid arthritis patients at 2 years is 59%; its use as a 2nd line biologic agent and lower baseline haq predict better survival in clinical practice: a prospective, observational single center study. , 2017, , .		0
182	THU0246â€¦The impact of classifying SLE patients with the SLICC-2012 versus the ACR-1997 classification criteria on early diagnosis, severity, and damage: data from the community-based cretan lupus registry. , 2017, , .		0
183	FRI0244â€¦Low dose of rituximab is effective for maintenance of clinical remission or low disease activity in patients with rheumatoid arthritis. , 2017, , .		0
184	AB0442â€¦Real-life experience with belimumab in systemic lupus erythematosus (SLE): control of disease activity and flares in a multicenter cohort. , 2017, , .		0
185	05.14â€¦Rna-seq profiling of hematopoietic stem cells in murine systemic lupus erythematosus (sle): validation and functional characterisation. , 2017, , .		0
186	SAT0330â€¦Lower prevalence but comparable clinical characteristics and prognosis of systemic sclerosis in crete-greece as compared to other european countries: a single center experience. , 2017, , .		0
187	FRI0236â€¦After discontinuation of the 1st tumor necrosis factor inhibitor (TNFI), non-tnfi biologic agents have similar responses but higher survival compared to a 2nd course of a different tnfi: long-term prospective observational study of patients with rheumatoid arthritis in a tertiary hospital of greece. , 2017, , .		0
188	O003â€¦Characterising the role of net-derived IL-33 in SLE pathogenesis. , 2018, , .		0
189	P009â€¦Transcriptomic analysis of plasmacytoid dendritic cells from rheumatoid arthritis patients reveals novel targets for therapy. , 2018, , .		0
190	P108â€¦Exploring the molecular basis of gender bias in systemic lupus erythematosus (SLE). , 2018, , .		0
191	P016â€¦Baseline levels of IL-17-producing CD4+ T cells predict clinical response to abatacept in rheumatoid arthritis patients. , 2018, , .		0
192	S4D:7â€¦Next generation sequencing in hematopoietic progenitors of murine sle model reveals aberrant regulation of cebp/a expression. , 2018, , .		0
193	S3D:7â€¦Cerebral hypoperfusion detected by perfusion-weighted mri may assist the diagnosis of primary diffuse neuropsychiatric lupus erythematosus. , 2018, , .		0
194	New respiratory symptoms and lung imaging findings in a woman with polymyositis. Breathe, 2018, 14, e34-e39.	1.3	0
195	AB0503â€¦Therapeutic strategy and short-term outcome in neuropsychiatric systemic lupus erythematosus. , 2018, , .		0
196	THU0299â€¦PATIENT GLOBAL ASSESSMENT OF DISEASE ACTIVITY IN BEHÇETÇS SYNDROME: A MULTICENTER STUDY. , 2019, , .		0
197	FRI0225â€¦THE EULAR/ACR 2018 AND SLICC 2012 HAVE INCREASED SENSITIVITY AGAINST THE ACR 1997 CLASSIFICATION CRITERIA AND CLASSIFY NON-OVERLAPPING GROUPS OF SLE PATIENTS: SIMULTANEOUS APPLICATION ASSURES THE GREATEST CAPTURE OF PATIENTS IN CLINICAL PRACTICE. , 2019, , .		0
198	AB0680â€¦NAIFOLD VIDEOCAPILLAROSCOPY PATTERN CORRELATES WITH ORGAN INVOLVEMENT AND DISEASE OUTCOME IN SYSTEMIC SCLEROSIS: A SINGLE-CENTER OBSERVATIONAL STUDY. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
199	SAT0240â€¦DEVELOPMENT AND PRELIMINARY VALIDATION OF THE BEHÄ†ETâ€™S SYNDROME OVERALL DAMAGE INDEX (BODI). , 2019, , .		0
200	THU0284â€¦WHAT DO HEMATOLOGICAL ABNORMALITIES TELL US IN SLE? RESULTS FROM TWO INDEPENDENT MULTICENTER EUROPEAN SLE COHORTS. , 2019, , .		0
201	OP0277â€¦RNA SEQUENCING AND MACHINE LEARNING TECHNIQUES PREDICT MAJOR ORGAN INVOLVEMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
202	SAT0161â€¦SUSTAINED MODERATE DISEASE ACTIVITY (SMDA) IN RHEUMATOID ARTHRITIS PATIENTS ON BIOLOGIC THERAPIES IS ASSOCIATED WITH 5 YEARS FUNCTIONAL LIMITATION AND SERIOUS ADVERSE EVENTSDEVELOPMENT; EVIDENCE TO SUPPORT TREAT-TO-TARGET APPROACH FOR PATIENTS IN SMDA AND ESPECIALLY THOSE IN HIGH SMDA. , 2019, , .		0
203	AB0678â€¦ANTIPROLIFERATIVE AND VASOACTIVE TREATMENT MODALITIES IN 457 CONSECUTIVE PATIENTS WITH SYSTEMIC SCLEROSIS FROM ACADEMIC CENTERS IN GREECE. , 2019, , .		0
204	FRIO192â€¦A SYSTEMATIC LITERATURE REVIEW TO INFORM THE 2019 UPDATE OF THE EULAR RECOMMENDATIONS FOR THE TREATMENT OF SYSTEMIC LUPUS ERYTHEMATOSUS. , 2019, , .		0
205	SAT0154â€¦STABILIZATION OF RHEUMATOID ARTHRITIS ASSOCIATED INTERSTITIAL LUNG DISEASEBY RITUXIMAB: A SINGLE CENTER EXPERIENCE WITH LONG-TERM FOLLOW-UP. , 2019, , .		0
206	FRIO411â€¦COMPARABLE CLINICAL RESPONSES BUT HIGHER TREATMENT ADHERENCE OF SECUKINUMAB COMPARED TO TNF INHIBITORS IN SPONDYLOARTHRITIS PATIENTS: LONG TERM PROSPECTIVE OBSERVATIONAL STUDY IN A TERTIARY HOSPITAL OF GREECE. , 2019, , .		0
207	P0359CROSS-TISSUE AND MURINE-HUMAN COMPARATIVE TRANSCRIPTOME ANALYSES IDENTIFY TARGETABLE GENES FOR HUMAN SYSTEMIC LUPUS ERYTHEMATOUS AND LUPUS NEPHRITIS. <i>Nephrology Dialysis Transplantation</i> , 2020, 35, .	0.7	0
208	11â€¦Remission and low disease activity: the new targets for treatment. , 2020, , .		0
209	Simultaneous presentation of Lupus Erythematosus in a mother and a sibling pair. <i>Australasian Journal of Dermatology</i> , 2020, 61, e434-e435.	0.7	0
210	Cytotoxic drug treatment. , 2021, , 611-620.		0
211	POS0370â€¦TYPE I INTERFERON PATHWAY ASSAYS IN PATIENTS WITH RHEUMATIC AND MUSCULOSKELETAL DISEASES - SYSTEMATIC LITERATURE REVIEW (SLR) AND DEVELOPMENT OF CONSENSUS TERMINOLOGY FROM A EULAR TASKFORCE. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 415-415.	0.9	0
212	OP0019â€¦DEFINING SYSTEMIC LUPUS ERYTHEMATOSUS MOLECULAR TAXONOMY THROUGH DATA-DRIVEN RESTRATIFICATION AND IDENTIFICATION OF CLUSTER-TAILORED DRUGS FOR A PERSONALIZED MEDICINE APPROACH. <i>Annals of the Rheumatic Diseases</i> , 2021, 80, 11.1-11.	0.9	0
213	Response to: Correspondence on â€œUpdate on the diagnosis and management of systemic lupus erythematosusâ€•by Zhou<i>et al</i>. <i>Annals of the Rheumatic Diseases</i> , 2023, 82, e192-e192.	0.9	0
214	A1.23â€¦IFNÎ± mediated deregulation of mitochondrial DNA clearance as an inciting event for the development of SLE autoimmunity. <i>Annals of the Rheumatic Diseases</i> , 2016, 75, A10.1-A10.	0.9	0
215	THU0072â€¦Gene signature of plasmacytoid dendritic cells reveals novel pathways contributing to tolerance in rheumatoid arthritis patients. , 2018, , .		0
216	Comparative analysis of the sensitivity and specificity of the classification criteria and correlation with prognosis of disease in patients with Systemic Lupus Erythematosus. <i>Mediterranean Journal of Rheumatology</i> , 2018, 29, 232-235.	0.8	0

#	ARTICLE	IF	CITATIONS
217	Response to: "Hydroxychloroquine is neutral in risk of chronic kidney disease in patients with systemic lupus erythematosus" by Wuet al. Annals of the Rheumatic Diseases, 2020, , annrhumdis-2020-217804.	0.9	0
218	The relation of partners' illness representations to the coping behaviors of patients with inflammatory rheumatic diseases through patients' illness representation: A dyadic regulation process. Current Psychology, 0, , 1.	2.8	0
219	Dialogue: High-throughput studies in rheumatology: time for unsupervised clustering?. Lupus Science and Medicine, 2021, 8, e000643.	2.7	0
220	Deciphering the Molecular Mechanism of Flares in Patients with Systemic Lupus Erythematosus through Single-Cell Transcriptome Analysis of the Peripheral Blood. Mediterranean Journal of Rheumatology, 2022, 33, 94.	0.8	0
221	Remission or low disease activity at pregnancy onset are linked to improved foetal outcomes in women with systemic lupus erythematosus: results from a prospective observational study.. Clinical and Experimental Rheumatology, 2022, , .	0.8	0